Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis

BACKGROUND: Pyrotinib, a small-molecule tyrosine kinase inhibitor, has been investigated as a component of neoadjuvant therapy in phase 2 trials of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This study aimed to evaluate the effectiveness and safety of pyrotinib-containin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Xiaoyun, Lv, Pengwei, Gong, Yiping, Wu, Xiujuan, Tang, Peng, Wang, Shushu, Zhang, Dianlong, You, Wei, Wang, Ouchen, Zhou, Jun, Li, Jingruo, Jin, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021502/
https://www.ncbi.nlm.nih.gov/pubmed/35463365
http://dx.doi.org/10.3389/fonc.2022.855512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021502/
https://www.ncbi.nlm.nih.gov/pubmed/35463365
http://dx.doi.org/10.3389/fonc.2022.855512

Ejemplares similares